A few companies have taken big strides in moving their biosimilar portfolios forward in Europe and the USA this year – with Samsung Bioepis, Boehringer Ingelheim and Amgen (Nasdaq: AMGN) among the undisputed frontrunners in this burgeoning field.
Their progress will have been watched with interest by Sandoz, a unit of Swiss pharma giant Novartis (NOVN: VX), which calls itself the global leader in biosimilars.
Sandoz strengthened that claim on Tuesday by releasing new immunology data from four clinical studies for proposed biosimilars of adalimumab and rituximab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze